ATE512949T1 - Reninhemmer - Google Patents

Reninhemmer

Info

Publication number
ATE512949T1
ATE512949T1 AT00922651T AT00922651T ATE512949T1 AT E512949 T1 ATE512949 T1 AT E512949T1 AT 00922651 T AT00922651 T AT 00922651T AT 00922651 T AT00922651 T AT 00922651T AT E512949 T1 ATE512949 T1 AT E512949T1
Authority
AT
Austria
Prior art keywords
renin inhibitors
renin
inhibitors
Prior art date
Application number
AT00922651T
Other languages
English (en)
Inventor
Volker Breu
Hans-Peter Maerki
Eric Vieira
Wolfgang Wostl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE512949T1 publication Critical patent/ATE512949T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT00922651T 1999-04-27 2000-04-19 Reninhemmer ATE512949T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99108199 1999-04-27
PCT/EP2000/003555 WO2000064873A1 (en) 1999-04-27 2000-04-19 Renin inhibitors

Publications (1)

Publication Number Publication Date
ATE512949T1 true ATE512949T1 (de) 2011-07-15

Family

ID=8238050

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00922651T ATE512949T1 (de) 1999-04-27 2000-04-19 Reninhemmer

Country Status (35)

Country Link
US (2) US6376672B1 (de)
EP (1) EP1175400B1 (de)
JP (1) JP3808706B2 (de)
KR (1) KR100443684B1 (de)
CN (1) CN1147471C (de)
AR (2) AR018719A1 (de)
AT (1) ATE512949T1 (de)
AU (1) AU763718B2 (de)
BR (1) BR0010080B1 (de)
CA (1) CA2370888C (de)
CO (1) CO5170513A1 (de)
CZ (1) CZ302012B6 (de)
DK (1) DK1175400T3 (de)
EG (1) EG23979A (de)
ES (1) ES2366668T3 (de)
GC (1) GC0000251A (de)
HK (1) HK1045999B (de)
HR (1) HRP20010762A2 (de)
HU (1) HU227764B1 (de)
IL (2) IL146002A0 (de)
JO (1) JO2256B1 (de)
MA (1) MA26787A1 (de)
MX (1) MXPA01010934A (de)
MY (1) MY127894A (de)
NO (1) NO320803B1 (de)
NZ (1) NZ514981A (de)
PE (1) PE20010069A1 (de)
PL (1) PL199895B1 (de)
PT (1) PT1175400E (de)
RS (1) RS51156B (de)
RU (1) RU2213731C2 (de)
TR (1) TR200103095T2 (de)
TW (1) TWI224593B (de)
WO (1) WO2000064873A1 (de)
ZA (1) ZA200108735B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6835686B2 (en) * 2001-07-05 2004-12-28 Millennium Specialty Chemicals Catalyst system and process for rearrangement of epoxides to allylic alcohols
US20060009497A1 (en) * 2002-06-27 2006-01-12 Actelion Pharmaceuticals, Ltd. Novel tetrahydropyridine derivatives as renin inhibitors
US20040214832A1 (en) * 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
CA2521932A1 (en) * 2003-04-29 2004-11-11 Actelion Pharmaceuticals Ltd Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives
TW200513461A (en) * 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
AR045950A1 (es) * 2003-10-09 2005-11-16 Speedel Experimenta Ag Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
WO2005037317A2 (en) * 2003-10-17 2005-04-28 Cornell Research Foundation, Inc. Mast cell-derived renin
RU2374228C2 (ru) * 2003-11-26 2009-11-27 Новартис Аг Производные 4-фенилпиперидина в качестве ингибиторов ренина
TW200613274A (en) * 2004-07-09 2006-05-01 Speedel Experimenta Ag Organic compounds
BRPI0516128A (pt) 2004-10-08 2008-08-26 Novartis Ag uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
TW200833687A (en) * 2005-03-31 2008-08-16 Speedel Experimenta Ag Substituted piperidines
EP1707202A1 (de) * 2005-03-31 2006-10-04 Speedel Experimenta AG Organische Verbindungen
US20090270380A1 (en) * 2005-03-31 2009-10-29 Peter Herold 3,4,5-Substituted Piperidines as Renin Inhibitors
EP1897879A3 (de) * 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-Substituierte Piperidine als Renin-Inhibitoren
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
CN101151262B (zh) * 2005-03-31 2011-07-06 斯皮德尔实验股份公司 取代的哌啶
NZ564689A (en) 2005-05-27 2011-02-25 Actelion Pharmaceuticals Ltd Novel piperidine carboxylic acid amide derivatives
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
BRPI0617621A2 (pt) * 2005-10-21 2011-08-02 Novartis Ag combinação de compostos orgánicos
CN101356156B (zh) * 2005-11-14 2012-12-05 生命医药公司 天冬氨酸蛋白酶抑制剂
EP1968940B1 (de) * 2005-12-30 2014-04-02 Novartis AG 3,5-substituierte piperidinverbindungen als renininhibitoren
EP1816122A3 (de) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituierte Piperidine als therapeutische Zusammensetzungen
TW200804359A (en) 2006-01-19 2008-01-16 Speedel Experimenta Ag Substituted 4-phenylpiperidines
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
WO2008021552A2 (en) * 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
EP1911758A1 (de) * 2006-10-04 2008-04-16 Speedel Experimenta AG Phenylpiperidinderivative zur Verwendung als Renin Inhibitoren
EP1908761A1 (de) * 2006-10-04 2008-04-09 Speedel Experimenta AG Organische Verbindungen
EP2527338B1 (de) 2007-06-25 2015-05-06 Novartis AG N5-(2-ethoxyethyl)-n3-(2-pyridinyl) -3,5-piperidinedicarboxamide derivate als renin inhibitoren
BRPI0819352A2 (pt) * 2007-11-02 2015-04-22 Novartis Ag Piperidinas 4,4-dissubstituídas
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
EP2488661B1 (de) 2009-10-14 2014-12-24 Oberbauer, Rainer Prüfung auf Risiko einer akuten Nierenverletzung
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
EP2810644A1 (de) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Orale Formulierung zur Behandlung von Herz-Kreislauf-Erkrankungen
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK231088D0 (da) 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
DE3640475A1 (de) 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
DE69119098T2 (de) 1991-06-24 1996-10-31 Optische Ind De Oude Delft Nv Vorrichtung zur beobachtung der atmung
WO1997003911A1 (de) 1995-07-24 1997-02-06 Railfix N.V. Elektro-permanentmagnetsystem zum manövrieren von einer magnetischen insbesondere ferromagnetischen last
ATE242213T1 (de) * 1995-09-07 2003-06-15 Hoffmann La Roche Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz
WO1999012532A2 (en) * 1997-09-08 1999-03-18 F.Hoffmann-La Roche Ag Piperidine derivatives against malaria
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors

Also Published As

Publication number Publication date
US20020087002A1 (en) 2002-07-04
JP3808706B2 (ja) 2006-08-16
NO320803B1 (no) 2006-01-30
AU763718B2 (en) 2003-07-31
NO20015206D0 (no) 2001-10-25
EP1175400B1 (de) 2011-06-15
IL146002A (en) 2007-03-08
CA2370888C (en) 2005-08-23
HRP20010762A2 (en) 2005-02-28
PT1175400E (pt) 2011-08-11
CA2370888A1 (en) 2000-11-02
JP2002543063A (ja) 2002-12-17
CN1349503A (zh) 2002-05-15
AU4296800A (en) 2000-11-10
MA26787A1 (fr) 2004-12-20
YU77101A (sh) 2004-09-03
PL353442A1 (en) 2003-11-17
NZ514981A (en) 2004-02-27
BR0010080B1 (pt) 2012-03-20
AR070473A2 (es) 2010-04-07
HU227764B1 (en) 2012-02-28
RS51156B (sr) 2010-10-31
CO5170513A1 (es) 2002-06-27
HUP0203669A2 (hu) 2003-02-28
TWI224593B (en) 2004-12-01
KR20010109529A (ko) 2001-12-10
HUP0203669A3 (en) 2003-12-29
US6376672B1 (en) 2002-04-23
EP1175400A1 (de) 2002-01-30
HK1045999B (zh) 2004-10-21
HK1045999A1 (en) 2002-12-20
GC0000251A (en) 2006-11-01
BR0010080A (pt) 2002-01-15
ZA200108735B (en) 2003-01-23
EG23979A (en) 2008-02-27
AR018719A1 (es) 2001-11-28
PL199895B1 (pl) 2008-11-28
WO2000064873A1 (en) 2000-11-02
IL146002A0 (en) 2002-07-25
PE20010069A1 (es) 2001-03-03
MY127894A (en) 2006-12-29
CZ302012B6 (cs) 2010-09-08
JO2256B1 (en) 2004-10-07
TR200103095T2 (tr) 2002-04-22
ES2366668T3 (es) 2011-10-24
KR100443684B1 (ko) 2004-08-09
MXPA01010934A (es) 2002-05-06
CZ20013854A3 (cs) 2002-04-17
CN1147471C (zh) 2004-04-28
NO20015206L (no) 2001-10-25
RU2213731C2 (ru) 2003-10-10
DK1175400T3 (da) 2011-07-18
US6673931B2 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
ATE512949T1 (de) Reninhemmer
DE60035039D1 (de) Renin inhibitoren
PT1181017E (pt) Inibidores de metaloproteases
PT1224195E (pt) C-aril-glicosidos inibidores de tgls2
ATE285821T1 (de) Fab i inhibitoren
EE200100492A (et) Ensüümi IMPDH inhibiitorid
PT1194404E (pt) Inibidores de aspartil-protease
ATE524441T1 (de) Vla-4-inhibitoren
EE200200069A (et) Metalloproteinaaside inhibiitoriteks olevad pürimidiin-3,4,6-trioonid
DE60008527D1 (de) Zellproliferation inhibitoren
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20014243L (no) Dihetero-substituerte metalloproteaseinhibitorer
NO20021658D0 (no) Asfaltenhemmere
NO20014875D0 (no) Promedikamenter for trombin inhibitorer
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
DE60024101D1 (de) Enzyminhibitoren
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren
NO20022924L (no) Farnesyltransferase-inhibitorer
IDP000027420A (id) Inhibitor-inhibitor kinase pirolotriazin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1175400

Country of ref document: EP